Boldenone and trenbolone monographs added

The two new entries extend the register that governs Ergopharm's sterile injectable portfolio. Each monograph fixes the finished-product specification for the ester in question: the declared strength, the release and shelf-life acceptance criteria, and the analytical procedures used to confirm identity, assay, sterility and endotoxin content before a batch can be released. With boldenone and trenbolone now documented alongside the existing entries, the oil-based injectable range stands at six esters, each held to the same set of controls.

“Adding an ester to the register means its specification, testing and pack identity are fixed and change-controlled, not decided batch by batch.”

For distributors, the practical significance is consistency of documentation. Every batch produced against these monographs is accompanied by a Certificate of Analysis referencing the same specification, is released by the Qualified Person against the Batch Manufacturing Record, and carries the serialised pack identity Ergopharm applies across its output: a GS1 DataMatrix encoding GTIN, expiry, batch and a unique serial. Adding the two esters to the formal register means their controls are versioned and change-controlled rather than handled case by case.

The finished-product testing behind each release follows harmonised compendial methods. Sterility is confirmed under USP <71>, bacterial endotoxins under the harmonised LAL chapter USP <85>, and injectable particulate matter under USP <788>. As oil-based sterile products, the esters are filled in classified areas under EU/WHO GMP Grade A conditions with the supporting Grade B background, and the water and clean-utility systems feeding the line are qualified through the standard IQ/OQ/PQ sequence.

For patients and prescribers, the monographs reinforce that these remain prescription-only, serialised medicines manufactured under GMP. Stability is assessed against ICH Q1A(R2) conditions to underwrite the assigned shelf life, and product-quality monitoring continues under the company's ICH Q10 pharmaceutical quality system, so any deviation, out-of-specification result or change is captured through the existing CAPA and change-control channels.